These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19112851)

  • 21. Safety and efficacy of pimecrolimus cream 1% in the daily practice: results of a patient self-observation study in patients with atopic dermatitis.
    Luger TA; Gollnick H; Schwennesen T; Bextermöller R; Freytag S; Bräutigam M
    J Dtsch Dermatol Ges; 2007 Oct; 5(10):908-14. PubMed ID: 17910673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin.
    Meingassner JG; Aschauer H; Stuetz A; Billich A
    Exp Dermatol; 2005 Oct; 14(10):752-7. PubMed ID: 16176283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.
    Langley RG; Luger TA; Cork MJ; Schneider D; Paul C
    Dermatology; 2007; 215 Suppl 1():27-44. PubMed ID: 18174691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
    Eichenfield LF; Thaci D; de Prost Y; Puig L; Paul C
    Dermatology; 2007; 215 Suppl 1():3-17. PubMed ID: 18174689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rosaceiform dermatitis with follicular Demodex after treatment of facial atopic dermatitis with 1% pimecrolimus cream.
    Lübbe J; Stucky L; Saurat JH
    Dermatology; 2003; 207(2):204-5. PubMed ID: 12920379
    [No Abstract]   [Full Text] [Related]  

  • 26. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review.
    Rustin MH
    Br J Dermatol; 2007 Nov; 157(5):861-73. PubMed ID: 17854353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial.
    Hoeger PH; Lee KH; Jautova J; Wohlrab J; Guettner A; Mizutani G; Hultsch T
    Br J Dermatol; 2009 Feb; 160(2):415-22. PubMed ID: 19067708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis.
    Aschoff R; Schwanebeck U; Bräutigam M; Meurer M
    Exp Dermatol; 2009 Jan; 18(1):24-9. PubMed ID: 18637133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis.
    Jensen JM; Pfeiffer S; Witt M; Bräutigam M; Neumann C; Weichenthal M; Schwarz T; Fölster-Holst R; Proksch E
    J Allergy Clin Immunol; 2009 May; 123(5):1124-33. PubMed ID: 19410693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
    Munzenberger PJ; Montejo JM
    Pharmacotherapy; 2007 Jul; 27(7):1020-8. PubMed ID: 17594208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis.
    Langley RG; Eichenfield LF; Lucky AW; Boguniewicz M; Barbier N; Cherill R
    Pediatr Dermatol; 2008; 25(3):301-7. PubMed ID: 18577032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pimecrolimus-induced rosacea-like demodicidosis.
    Yoon TY; Kim HJ; Kim MK
    Int J Dermatol; 2007 Oct; 46(10):1103-5. PubMed ID: 17910727
    [No Abstract]   [Full Text] [Related]  

  • 33. Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream.
    Gorman CR; White SW
    Arch Dermatol; 2005 Sep; 141(9):1168. PubMed ID: 16172323
    [No Abstract]   [Full Text] [Related]  

  • 34. Control of atopic eczema with pimecrolimus cream 1% under daily practice conditions: results of a > 2000 patient study.
    Ring J; Abraham A; de Cuyper C; Kim K; Langeland T; Parra V; Pigatto P; Reunala T; Szczepanski R; Möhrenschlager M; Bräutigam M; Rossi AB; Meents-Kopecky E; Schneider D
    J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):195-203. PubMed ID: 18211413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pimecrolimus (SDZ ASM 981). Current state of research].
    Dissemond J; Goos M; Wagner SN
    Dtsch Med Wochenschr; 2002 May; 127(22):1199-203. PubMed ID: 12035117
    [No Abstract]   [Full Text] [Related]  

  • 36. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
    Gebben HJ
    Ned Tijdschr Geneeskd; 2005 Aug; 149(32):1816-7; author reply 1817. PubMed ID: 16121670
    [No Abstract]   [Full Text] [Related]  

  • 37. Insight into pimecrolimus experience in seborrheic dermatitis: close follow-up with exact mean cure and remission times and side-effect profile.
    Tatlican S; Eren C; Eskioglu F
    J Dermatolog Treat; 2009; 20(4):198-202. PubMed ID: 19255921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks.
    Qureshi AA; Fischer MA
    Arch Dermatol; 2006 May; 142(5):633-7. PubMed ID: 16702502
    [No Abstract]   [Full Text] [Related]  

  • 39. Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis.
    Sigurgeirsson B; Ho V; Ferrándiz C; Andriano K; Grinienko A; Jimenez P;
    J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1290-301. PubMed ID: 18624866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream.
    Abramovits W; Fleischer AB; Jaracz E; Breneman D
    J Drugs Dermatol; 2008 Dec; 7(12):1153-8. PubMed ID: 19137769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.